Compared to these overpriced PD-1/PD-L1 antibodies, our findings demonstrated that the price reduction of camrelizumab provides a more promising opportunity to balance the efficacy and costs as first-line treatment against advanced NSCLC in resource-limited countries such as China. Here, PDCD1 is linked to non-small cell lung carcinoma.